News & Updates
Showing Multidisciplinary articles
Showing

Avacincaptad pegol slows geographic atrophy progression
Patients with noncentre point-involving geographic atrophy (GA) who receive avacincaptad pegol (ACP) 2 mg every month (EM) or every other month (EOM) show a persistent decrease in GA growth over 2 years relative to sham therapy, with no new safety signals, according to the GATHER2 study.
Avacincaptad pegol slows geographic atrophy progression
1 hour ago
2-year data support nerve-sparing technique in prostate cancer surgery
An updated 24-month analysis of the NeuroSAFE PROOF study continues to support robot-assisted radical prostatectomy (RARP) guided by the nerve-sparing NeuroSAFE technique in men with prostate cancer.
2-year data support nerve-sparing technique in prostate cancer surgery
3 hours ago
Pre-TURBT mitomycin-C improves RFS in NMIBC
In the updated 5-year analysis of a randomized phase II trial, administering two doses of intravesical mitomycin-C (MMC) immediately before transurethral resection of bladder tumour (TURBT) improves recurrence-free survival (RFS) in individuals with non-muscle invasive bladder cancer (NMIBC).






